Emergent BioSolutions Inc.

We are a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate and naturally occurring Public Health Threats ( PHTs ). Our solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing ( CDMO ) services portfolio. The types of PHTs we are currently addressing are focused on the following four categories: chemical, biological, radiological, nuclear and explosives ( CBRNE ); emerging infectious diseases ( EID ); emerging health crises; and acute, emergency and community care. Our revenues are derived from a combination of the sale and procurement of our product/product candidate portfolio (described below), the provision of our bioservices to external customers, and non-dilutive contract and grant funding for research and development ( R&D ) projects from various third-party sources. As of December 31, 2025, the Company has a portfolio of 11 products focused on addressing global public health threats like smallpox, mpox, anthrax, Ebola and opioid overdose emergencies. The revenues generated by the products comprise a substantial portion of our revenue. We structure our business with a focus on markets and customers. As such, the key components of the business structure include the following four product and service categories: Commercial products, consisting of NARCAN Nasal Spray and KLOXXADO , Anthrax Medical Countermeasures ( MCM ) Products, Smallpox - MCM products, and Emergent Bioservices (CDMO) ( Bioservices ).